{"id":338085,"date":"2025-12-11T02:28:21","date_gmt":"2025-12-11T02:28:21","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/338085\/"},"modified":"2025-12-11T02:28:21","modified_gmt":"2025-12-11T02:28:21","slug":"how-data-is-shaping-vaginal-microbiome-and-uti-care","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/338085\/","title":{"rendered":"How Data Is Shaping Vaginal Microbiome and UTI Care"},"content":{"rendered":"

\"Vaginal<\/p>\n

Evvy’s At Home UTI Diagnostic Kit<\/p>\n

Evvy uses advanced microbiome and PCR diagnostics to improve care for BV, UTIs, fertility, and vaginal health.<\/p>\n

Women who struggle with urinary tract infections that keep coming back, stubborn bacterial vaginosis, or persistent vaginal discomfort know the cycle all too well: a short appointment, a limited test, another round of antibiotics, and reassurance that \u201ceverything looks normal.\u201d For millions of women, the issue isn\u2019t their bodies\u2014it\u2019s a diagnostic system stuck in decades-old tools.<\/p>\n

Evvy, cofounded by Priyanka Jain, is focused on vaginal healthcare<\/a> and is working to change that system by uncovering what standard testing often misses, using an extensive dataset of vaginal microbiome samples.<\/p>\n

Today, Evvy launched its UTI+ Test, an at-home urine test that uses PCR technology to detect 12 uropathogens and seven antibiotic-resistance markers, delivering results within one business day. It aims to give women faster, clearer insight into infections that represent a $10.4 billion global market<\/a> today and are projected to reach $15 billion by 2032.<\/p>\n

The Scale Of BV And UTI Problems<\/p>\n

Evvy’s founding team: Laine Bruzek, Chief Marketing Officer; Priyanka Jain, CEO, Pita Navarro, Chief Scientific Officer<\/p>\n

NERO MEDIA<\/p>\n

Bacterial vaginosis and urinary tract infections are among the most common reasons women seek medical care. Yet the diagnostic tools remain outdated. The prescription drug market for bacterial vaginosis is forecast to more than double over the next decade, increasing from $1.1 billion in 2023<\/a> to an estimated $2.5 billion by 2033. UTIs drive millions of clinical visits each year and absorb billions in treatment costs\u2014yet nearly half of women receive antibiotics that are not considered first-line therapy.<\/p>\n

Part of the challenge is that standard urine cultures miss up to 50% to 70% of pathogens<\/a> in women with symptoms. Vaginal testing, meanwhile, still often relies on a clinician\u2019s visual reading under a microscope or a \u201cwhiff test\u201d\u2014using your nose to notice an odor.<\/p>\n

\u201cThe whole system does not want women to have more agency, more information, and it\u2019s wild how much inertia there is to fight against,\u201d explained Jain, Evvy\u2019s CEO. \u201cIt shows why women have gone so long without real answers.\u201d<\/p>\n

Evvy has raised $19 million in funding, backed by General Catalyst and Left Lane Capital. \u201cEvvy\u2019s groundbreaking platform is changing the way we understand and care for the female body,\u201d said Laura Sillman, VP at Left Lane Capital.<\/p>\n

How Evvy\u2019s Model Improves Vaginal And UTI Care<\/p>\n

Evvy at-home sample collection tube<\/p>\n

Evvy uses advanced microbiome and PCR diagnostics to improve care for BV UTIs, fertility, and vaginal health. <\/p>\n

Evvy\u2019s founding thesis is straightforward: Women have been underserved because medicine has lacked high-resolution tools to understand the vaginal and urinary microbiomes. Evvy can detect more than 700 bacteria and fungi from a single swab, offering a level of detail that older methods cannot approach. A peer-reviewed validation<\/a> found that Evvy reached 93.1% sensitivity and 90% specificity.<\/p>\n

Evvy\u2019s at-home vaginal test has become core to its clinical research, including a published outcomes study that found 75.5% of users experienced symptom relief<\/a> after personalized treatment guided by microbiome results, with far lower return-of-symptom rates than with standard care.<\/p>\n

Today, Evvy has expanded beyond vaginal testing with the launch of UTI+, a PCR-based urine test that identifies 12 pathogens and seven antibiotic-resistance markers. The test offers a one-business-day turnaround and enables targeted treatment within 24 hours\u2014an essential shift from slow cultures and empiric antibiotic prescribing.<\/p>\n

The Barriers In Women\u2019s Health CareClinical Inertia In Women\u2019s Health Testing<\/p>\n

Evvy\u2019s work also exposes deeper structural challenges. Traditional diagnostics were not designed to distinguish between mixed infections, antibiotic-resistance markers, or subtle microbiome shifts that can trigger ongoing symptoms. Clinicians often lack tools that go beyond broad categories like \u201cBV-positive\u201d or \u201cUTI-negative.\u201d<\/p>\n

Changing that ecosystem requires research, which Evvy has aggressively pursued. The company has ongoing clinical trials in BV, UTIs, fertility, IVF outcomes, and menopause-related vaginal changes. Its scientific advisory relationships span leading academic and clinical institutions. More than 2,000 healthcare providers have interacted with or referred patients to Evvy.<\/p>\n

Still, early skepticism was real. Some clinicians were concerned that giving women detailed microbial data would overwhelm them. Evvy found the opposite: Clarity reduces anxiety. Most patients want more information about their bodies, not less.<\/p>\n

Educating Payors And Policymakers: Access And Reimbursement <\/p>\n

Today, Evvy remains a cash-pay service, not because of strategy but because insurers are reluctant to reimburse more advanced diagnostics. Legacy methods like microscopy or the whiff test cost very little, and payors have not yet adapted to microbiome science.<\/p>\n

Evvy is working to change that through clinical trials that link microbiome profiles to high-cost issues such as unsuccessful IVF cycles, preterm birth risk, and persistent vaginal symptoms that often lead to repeated visits and antibiotic courses. Demonstrating cost savings and clinical impact will be essential to shifting coverage.<\/p>\n

Navigating Algorithm Bias In Women\u2019s Health<\/p>\n

Digital platforms present another challenge uniquely familiar to women\u2019s health companies. Content containing medically accurate phrases like \u201cvaginal health,\u201d \u201cBV symptoms,\u201d or \u201cUTI testing\u201d can be flagged or down-ranked by social media and search algorithms, limiting reach.<\/p>\n

This environment makes community-building and education difficult. Yet it also reinforces why direct-to-consumer access matters: Women are seeking answers outside traditional medical systems, and they want tools that offer clarity rather than more ambiguity.<\/p>\n

Evvy\u2019s Patient-First Care Approach<\/p>\n

What distinguishes Evvy is not only advanced testing, but how results translate into care. Evvy pairs test findings with personalized treatment plans by doctors designed to address the root cause of symptoms and prevent recurrence. The company provides follow-up guidance and care pathways tailored to an individual\u2019s microbial profile.<\/p>\n

\u201cWe fix the symptom, we fix the problem, and we make sure it doesn\u2019t come back,\u201d Jain said. \u201cAnd we do all of that while giving women a good experience where they feel understood and listened to.\u201d<\/p>\n

The company\u2019s patient-centered approach is reflected in a striking metric: 98% of users consent to participate in research, which strengthens the data available to improve women\u2019s health outcomes.<\/p>\n

\u201cThrough this strategic partnership with Evvy, we aim to create a patient-first experience that helps women more conveniently access the treatments they need for their health,\u201d noted Elizabeth Stephens, director, Women\u2019s Health Strategy, Advocacy, and Partnerships at Organon. <\/p>\n

A New Standard For Vaginal And UTI Care And BeyondEvvy\u2019s Expanding Role In Fertility And Menopause<\/p>\n

Beyond UTIs and BV, Evvy is exploring how the vaginal microbiome affects fertility and pregnancy. Early research shows connections between microbiome imbalances and inflammation that can affect implantation. Evvy is working with fertility clinics to explore how microbiome-guided care might improve IVF outcomes.<\/p>\n

The company is also developing approaches for menopause, when estrogen decline reshapes the vaginal microbiome and increases susceptibility to infection and irritation. Evvy is studying how personalized hormonal and microbiome treatments may better support midlife health.<\/p>\n

How Precision Tools Improve Women\u2019s UTI And BV Care<\/p>\n

Evvy\u2019s work is part of a broader shift in women\u2019s health toward tools that offer specificity rather than broad categories, answers rather than assumptions, and prevention rather than repeated cycles of treatment. The December launch of UTI+ signals how far the company has come and how much opportunity lies ahead.<\/p>\n

As the medical field continues to recognize the importance of the vaginal and urinary microbiomes, Evvy\u2019s data-driven model offers a path toward care that is faster, more accurate, and more aligned with women\u2019s lived experiences. For many, it may finally provide the clarity they have long been denied, setting a new bar for vaginal microbiome and UTI diagnostic care.<\/p>\n","protected":false},"excerpt":{"rendered":"Evvy’s At Home UTI Diagnostic Kit Evvy uses advanced microbiome and PCR diagnostics to improve care for BV,…\n","protected":false},"author":2,"featured_media":338086,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[148273,49,48,84,392,148275,148272,148276,148271,148274],"class_list":{"0":"post-338085","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-bacterial-vaginosis-bv","9":"tag-ca","10":"tag-canada","11":"tag-health","12":"tag-healthcare","13":"tag-precision-womens-healthcare","14":"tag-recurrent-utis-uti-test-at-home-uti-testing","15":"tag-uti-diagnostic-care","16":"tag-vaginal-microbiome","17":"tag-womens-health-innovation"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/338085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=338085"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/338085\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/338086"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=338085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=338085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=338085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}